|
Originally published In Press as doi:10.1074/jbc.M108077200 on October 8, 2001
J. Biol. Chem., Vol. 276, Issue 51, 48596-48607, December 21, 2001
Intracellular Localization of the Ret Finger Protein
Depends on a Functional Nuclear Export Signal and Protein Kinase C
Activation*
Matthias
Harbers ,
Teruaki
Nomura §,
Shigeo
Ohno¶, and
Shunsuke
Ishii §
From the Laboratory of Molecular Genetics, RIKEN
Tsukuba Institute, and § Core Research for Evolutionary
Science and Technology (CREST) Project of Japan Science and Technology
Corporation, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, and the
¶ Department of Molecular Biology, Yokohama City University School
of Medicine, 3-9 Fuku-ura, Kanazawa-ku, Yokohama 236, Japan
Received for publication, August 22, 2001, and in revised form, September 28, 2001
 |
ABSTRACT |
The Ret finger protein (RFP) was
identified initially as an oncogene product and belongs to a family of
proteins that contain a tripartite motif consisting of a RING finger, a
B box, and a coiled-coil domain. RFP represses transcription by
interacting with Enhancer of Polycomb and is localized to the cytoplasm
or nucleus depending on the cell type. Here, we have identified the nuclear export signal (NES) located in the coiled-coil region of RFP.
Mutation of this NES or treatment with leptomycin B abrogated the
nuclear export of RFP in NIH3T3 cells. In addition, fusion of this NES
to other nuclear proteins, such as yeast transcription factor Gal4,
resulted in their release into the cytoplasm of NIH3T3 cells. Although
the NES function of RFP in HepG2 cells is masked by another domain in
RFP or by another protein,
12-O-tetradecanoylphorbol-13-acetate treatment or
overexpression of constitutively active protein kinase C (PKC )
abrogated masking, leading to the cytoplasmic localization of RFP.
Furthermore, treatment of NIH3T3 cells with PKC inhibitors blocked the
function of NES, resulting in nuclear localization of RFP. Thus, the
nuclear export of RFP is regulated positively by PKC activation.
However, RFP was not a direct substrate of PKC, and additional
signaling pathways may be involved in the regulation of nuclear export
of RFP.
 |
INTRODUCTION |
To fulfill their functions in complex organisms, most proteins
possess specialized domains that have been conserved throughout evolution. Depending on their overall domain structure, proteins have
been grouped into gene families, whose members often share similar
functions in cells or organisms. Members of one such gene family, the
RING-B box-coiled-coil
(RBCC)1 family (1), are
characterized by their possession of a tripatic motif consisting of a
RING finger (2, 3), one or two B boxes (4), and an -helical
coiled-coil domain (5). These domains are involved in protein-protein
interactions and allow RBCC family members to participate in various
cellular processes depending on their subcellular localization. In
transformed cells, three members of the RBCC family (PML,
transcriptional intermediary factor 1 , and RFP) were found to
be oncogenic after their RBCC domains were linked to other proteins by
DNA rearrangements. In acute promyelocytic leukemia cells, a reciprocal
chromosomal translocation fuses the PML gene with the retinoic acid
receptor gene, resulting in the expression of a PML-RAR fusion
protein (6, 7) that blocks hematopoiesis at the promyelocytic stage (8,
9). Similarly, the N-terminal RBCC domain of transcriptional
intermediary factor 1 recombines with the serine/threonine
kinase domain of B-Raf in the T18 oncogene (10), and the N terminus of
the Ret finger protein (RFP) was found to be fused to the
ret proto-oncogene (11) in transformed NIH3T3 cells (12,
13). The RBCC motifs are required for the transforming capacities of
these oncogenes (14), and oncogenesis may depend on the distinct
cellular localizations of the fusion proteins (9, 15).
After the identification of the oncogenic RFP-Ret fusion protein
in NIH3T3 cells, RFP was cloned from human (13) and mouse (16) and
found to be highly expressed in pachytene spermatocytes and round
spermatids during spermatogenesis, suggesting that it participates in
male germ cell differentiation (16, 17). Depending on the cell type or
tissue, RFP is localized either to the cytoplasm or nucleus (16, 17).
This localization requires the RBCC motif and homodimerization through
the coiled-coil domain (18). In the nucleus, RFP associates with the
nuclear matrix (19) and is a component of PML nuclear bodies (20) where
it binds directly to PML (21). Furthermore, RFP can interact with the
int-6 gene product, another component of PML nuclear bodies
(22). Recently, RFP was shown to repress transcription by interacting
with Enhancer of Polycomb (23), a member of Polycomb proteins. The
Polycomb group proteins were originally identified in
Drosophila as being involved in the maintenance of the
correct expression pattern of homeotic genes. Polycomb group proteins
form a large macromolecular complex and are involved in the epigenetic
gene silencing. However, no biological function has yet been defined
for RFP in the nucleus or cytoplasm, and mechanisms governing RFP
subcellular localization remain largely unknown.
The separation of the cytoplasm and nucleus in eukaryotic cells
provides an important way to regulate cellular processes through compartmentalization. As was shown for NF-AT (24) or I B (25, 26),
nuclear import and export through the nuclear envelope can control gene
expression in a signal-dependent manner by restricting the
access of transcription factors to their target genes. The exchange
between cytoplasm and nucleus occurs through the nuclear pore complex,
and this process is mediated in most cases by specific amino acid
sequences. Localization sequences exist for nuclear localization
(nuclear localization sequence, NLS) (27, 28) and for nuclear export
(nuclear export signal, NES) (29-31). The leucine-rich NES is
specifically recognized by CRM1, which functions as an export receptor
mediating the fast release of proteins with this sequence from the
nucleus (32-34). Masking of the NLS or NES through their binding to
other factors or through post-translational modifications would allow
for controlled shuttling of factors between the cytoplasm and the nucleus.
Here we have studied the cellular localization of RFP and found that it
can shuttle between the cytoplasm and the nucleus. Nuclear export of
RFP is dependent on a functional NES, which can be activated by protein
kinase C (PKC). The regulation of RFP localization by PKC points to an
important role for RFP in the control of cellular differentiation and proliferation.
 |
MATERIALS AND METHODS |
Cell Culture--
The NIH3T3 and HepG2 cells were maintained at
37 °C in a 5% CO2-containing atmosphere using
Dulbecco's modified Eagle's medium (Nissui Pharmaceuticals) with 10%
bovine calf serum (HyClone) or 10% fetal calf serum (Roche),
respectively. 12-O-Tetradecanoylphorbol-13-acetate (TPA),
H7, and staurosporine were obtained from Sigma. Leptomycin B (LMB) was
a gift from Dr. M. Yoshida. Drug concentrations and incubation times
are indicated in the figure legends. Serum concentrations were reduced
to 2% when drugs were added to the cell cultures.
Expression Vectors--
FLAG-tagged forms of RFP were
expressed from pSG5-FLAG-Nt, and Gal4 fusion proteins from pCMX-Gal4
and pG4polyII (35). For the expression of GFP fusion proteins,
the vectors pEGFP-C2, pEGFP-C3, pEGFP-N3, and pEYFP-nuc
(CLONTECH) were used. Mutations in the putative NES
and PKC phosphorylation sites were introduced by polymerase chain
reaction and verified by DNA sequencing. Expression vectors for PKC
were described by Ueda et al. (36). To express the activated
Ha-Ras, the SV40 promoter-containing vector pcEXV-1 was used.
The SR promoter-containing vector was used to express Jun N-terminal
protein kinase 1 (JNK1).
Immunohistochemistry--
Subcellular localization of RFP and
colocalization with other proteins were determined as described by Khan
et al. (37). For each 3-cm dish, 2 × 105
NIH3T3 cells or 4 × 105 HepG2 cells were seeded, and
on the next day the cells were transfected with 3 or 1.5 µg of the
expression vector using LipofectAMINE (Life Technologies, Inc.).
48 h after transfection, cells were fixed and stained with mouse
monoclonal anti-FLAG antibody M2 (Sigma) and rabbit polyclonal
antibodies against PKC (Santa Cruz). Fusion proteins containing the
DNA binding domain of Gal4 (Gal4-DBD) were detected by mouse monoclonal
anti-Gal4-DBD antibody (Santa Cruz). The signals were visualized by
rhodamine- or fluorescein isothiocyanate-conjugated secondary
antibodies (Jackson ImmunoResearch), and analyzed by confocal
microscopy (Zeiss LSM510). Nuclear DNA was stained with
TO-PRO®-3 iodide (Molecular Probes) and used as a nuclear
marker. GFP fusion proteins were analyzed in the same way directly
after fixation and DNA staining with TO-PRO®-3 iodide. In
Figs. 7-9, two types of staining pattern, which showed the
predominantly nuclear or cytoplasmic RFP, were observed, and the cells
showing uniform distribution in both nucleus and cytoplasm were not
detected. Approximately 50-150 cells were examined, and the
percentages of cells with cytoplasmic RFP were calculated. Photographs
and numbers from representative experiments are shown in the figures.
Yeast Two-hybrid Assay--
The homodimerization of RFP was
studied by the LexA yeast two-hybrid system in the strain L40 (38)
using the vectors pBTM116 (38) for the expression of LexA fusion
proteins and pASV3 (39) for the expression of VP16 fusion proteins.
-Galactosidase assays on individual transformants were carried out
as described in Ref. 40.
Western Blotting and PKC Activity--
PKC activity in NIH3T3
and HepG2 cells was measured in crude extracts using a PKC assay kit
(Calbiochem). Detection of PKC and a phosphorylated form of
PKC / (Thr-638) was performed by Western blotting using 50 µg of
total protein from NIH3T3 and HepG2 cells, anti-PKC (C-20, Santa
Cruz), or an anti-phospho-PKC / (Thr-638) antibody (New England BioLabs).
 |
RESULTS |
A Specific Domain of RFP Is Required for Its Cytoplasmic
Localization in NIH3T3 Cells--
RFP is highly expressed in tumor
cell lines, and its subcellular localization depends on cell type.
Exogenously expressed mouse RFP is located predominantly in the
cytoplasm of NIH3T3 cells, whereas it is localized in the nucleus of
HepG2 cells (18). We therefore chose NIH3T3 and HepG2 cells to study
mechanisms that control human RFP shuttling between the nucleus and
cytoplasm. Expression vectors for FLAG-tagged RFP (Fig.
1A) or an enhanced green
fluorescent protein (EGFP)-labeled form of RFP were transfected into
NIH3T3 and HepG2 cells, and their localization was analyzed by confocal
microscopy using TO-PRO®-3 iodide as a nuclear marker. As
expected, both forms of human RFP were found in the cytoplasm of NIH3T3
cells (Fig. 1B), associated with structures that resembled
the endoplasmic reticulum or Golgi apparatus. Depending on the
expression level, RFP showed a grainy pattern or clear dot-like
structures. Small amounts of RFP were also visible in the nucleus,
where they appeared as small dots. In contrast to NIH3T3 cells, both
forms of human RFP localized to the nucleus of HepG2 cells (Fig.
1C). Staining was observed for the whole nucleoplasm with
some preferences for the perinuclear region. Although RFP was reported
to associate with PML nuclear bodies (21), colocalization of RFP and
PML nuclear bodies was observed only at low frequency.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 1.
Subcellular localization of RFP in
NIH3T3 and HepG2 cells. Panel A, schematic
representation of FLAG-RFP protein. The domain structure containing the
Ring finger (R), B box (B), and coiled-coil
region (c-c) is shown. Panels B and C,
subcellular localization of RFP. NIH3T3 (panel B) and HepG2
(panel C) cells were transfected with 3-µg expression
vectors for FLAG-tagged RFP or a GFP-labeled form of RFP
(EGFP-RFP). FLAG-RFP was visualized with an anti-FLAG and a
rhodamine-conjugated secondary antibody, whereas the EGFP fusion
protein was visualized directly. Nuclear DNA was stained with
TO-PRO®-3 iodide (TO-PRO). Images were taken
through a confocal microscope. In the right images, both
signals are superimposed.
|
|
We next analyzed the mechanisms controlling the cytoplasmic
localization of RFP in NIH3T3 cells. Because N-terminally linked EGFP-RFP fusion proteins showed a localization similar to that of
FLAG-tagged RFP in both NIH3T3 and HepG2 cell lines (Fig. 1), EGFP-labeled deletion mutants of RFP were used to determine which domains of RFP affected its localization in NIH3T3 cells. Expression vectors encoding EGFP alone or EGFP fusion proteins for N-terminal and
C-terminal deletion mutations of RFP were transfected into NIH3T3
cells, and their subcellular localization was analyzed along with a
nuclear marker (Fig. 2). The EGFP control
protein was localized in both the nucleus and cytoplasm because its
small molecular mass of 27 kDa allows it to diffuse freely into
the nucleus. However, the RFP fusion proteins used in this study had molecular masses in excess of 40 kDa, which may preclude their passive
diffusion into the nucleus (30). Although the deletion of the RING
finger domain of RFP (RFP96-513) had little effect on RFP
localization, further deletion of the RING finger and B box, as in
EGFP-RFP(132-513), led to distinct patterns of localization. Although
the dot-like structures in the cytoplasm were maintained, increased
staining of the nucleoplasm was observed. An additional deletion of the
coiled-coil region (EGFP-RFP(315-513)) resulted in the disappearance
of the dot-like structures in the cytoplasm and redistribution of RFP
throughout the whole cell with a preference for the nucleus. A similar
pattern was observed for a mutant lacking the C-terminal part of RFP,
which contains the RING finger and the B box (EGFP-RFP(1-132)),
although the distribution between the cytoplasm and nucleus was more
uniform. Addition of the coiled-coil region to the RING finger and the
B box (EGFP-RFP(1-258)) reestablished the localization of RFP as
dot-like structures in the cytoplasm. Because the deletion analysis of
RFP pointed to an overall importance of the coiled-coil region for RFP
localization, a deletion mutant of RFP (EGFP-RFP cc), lacking the
coiled-coil region, was constructed, and its subcellular localization
was analyzed. As expected, the protein was distributed throughout the
whole cell with preferential localization to the nucleus. These results
indicate that the coiled-coil region is required for the cytoplasmic
localization of RFP in NIH3T3 cells.

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 2.
Domains of RFP involved in its subcellular
localization in NIH3T3. Vectors expressing RFP deletion mutants
fused to GFP were constructed as indicated, and 3 µg of each plasmid
was transfected into NIH3T3 cells. GFP fusion proteins were visualized
directly after fixation. Nuclear DNA was stained with
TO-PRO®-3 iodide (TO-PRO). Images were taken
through a confocal microscope. In the right images, both
signals are superimposed.
|
|
Identification of the NES in RFP--
The results described above
led us to speculate about the presence of an NES in the coiled-coil
region of RFP. In fact, sequence analysis of the coiled-coil region of
RFP revealed the putative leucine-rich NES (41, 42). An alignment of
the consensus NES (41-45) with the putative leucine-rich NES of RFP
indicated a perfect homology (Fig.
3A). To examine whether RFP
contains a functional NES, the three most conserved leucine residues in
the putative NES of RFP (Leu-204, Leu-207, and Leu-209 in Fig.
3A) were mutated to alanines, and the localization of the
mutated RFP (RFPmut) as a FLAG-tagged fusion protein was analyzed by
immunostaining (Fig. 3B). RFPmut was located predominantly
in the nucleus of NIH3T3 cells, and in some of those cells it localized
in dot-like structures similar to PML nuclear bodies. In addition,
NIH3T3 cells transfected with the RFP expression vector were treated with the CRM1 inhibitor LMB (31, 46) (Fig. 3B). Treatment of
NIH3T3 cells with LMB enhanced the nuclear localization of RFP. Similar
to RFPmut, wild-type RFP in LMB-treated cells could be seen in the
whole nucleus or in some cases in dot-like structures.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 3.
NES in the coiled-coil domain of RFP.
Panel A, alignment of the putative NES in RFP with the
leucine-rich NES of Hp120ctn (43), hcycB1 (44), mitogen-activated
protein kinase kinase (MAPKK) (45), protein kinase A inhibitor
(PKI) (42), and Rev (41). Panel B, effect of LMB and
mutations in the putative NES on the subcellular localization of RFP.
Wild-type or mutated forms of RFP were expressed as FLAG-tagged
proteins in NIH3T3 cells and stained with anti-FLAG antibody. In the
case of wild-type RFP, transfected cells were also treated with 4 ng/ml
LMB for 24 h. FLAG-tagged forms of RFP and DNA staining were
visualized through a confocal microscopy as described in Fig.
1B.
|
|
NES function can be studied by linking it to nuclear proteins, such as
the DNA binding domain of the yeast transcription factor Gal4
(Gal4-DBD), which changes its subcellular localization from the nucleus
to the cytoplasm when fused to an NES (47). To study the function of
the putative NES in RFP, the full-length RFP and the coiled-coil
regions of RFP, comprising either normal or mutated versions of the
putative NES, were expressed as Gal4-DBD fusion proteins in NIH3T3
cells, and their subcellular localizations were analyzed using
anti-Gal4-DBD antibody (Fig.
4A). In contrast to the
Gal4-DBD control protein, the wild-type RFP fusion protein was
localized preferentially to the cytoplasm, and mutations in the
putative NES resulted in relocalization of the Gal4-DBD-RFP fusion
protein to the nucleus. Similar results were obtained with Gal4-DBD
fused to the coiled-coil regions of RFP. The wild-type coiled-coil
region of RFP was able to relocate the Gal4-DBD to the cytoplasm. This
relocation was again blocked by point mutations in the putative NES. In
the addition to the cytoplasmic and nuclear localization, fusion
proteins of the Gal4-DBD with the coiled-coil region of RFP were found
in filament-like structures when the fusion proteins were expressed at
very high levels (data not shown). Thus, the NES in the coiled-coil
region can function alone.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 4.
Subcellular localization of nuclear proteins
fused to RFP derivatives. Panel A, effect of RFP on the
localization of Gal4-DBD. RFP and RFPmut as well as their coiled-coil
regions were fused to Gal4-DBD, and fusion proteins were expressed in
NIH3T3 cells. Immunohistochemistry was performed with an anti-Gal4-DBD
antibody as described in the legend of Fig. 1B. Panel
B, effect of RFP on the localization of nuclear GFP protein
(EYFPnuc). The three indicated RFP proteins were fused to
the GFP protein containing an NLS (EYFPnuc), and their
localizations in NIH3T3 cells were analyzed using a confocal microscopy
as described in Fig. 1B.
|
|
To confirm the function of the NES in RFP further, we also fused the
RFP protein derivatives to the nuclear form of GFP, which harbors three
NLS signals (EGFPnuc). The expression vectors for various EGFPnuc-RFP
fusion proteins were transfected into NIH3T3 cells, and their
subcellular localizations were analyzed (Fig. 4B). Similar
to the results obtained with the Gal4-DBD fusion proteins, wild-type
RFP was again able to relocalize EGFPnuc to the cytoplasm. NES
mutations led to nuclear localization of the fusion protein to the
dot-like structure that resembled those of PML. In contrast, however,
fusions of RFPmut with Gal4-DBD were almost uniformly distributed
throughout the nucleoplasm (Fig. 4A). This difference could
be because, unlike EGFPnuc, Gal4-DBD has DNA binding activity. Because
RFP was reported to form nuclear dot-like structure under certain
conditions (21), the DNA binding activity of Gal4-DBD may disturb the
localization of the fusion proteins to the nuclear dot-like structure.
Deletion of the coiled-coil region also resulted in nuclear
localization of RFP. However, these fusion proteins were distributed
throughout an entire nucleoplasm. Thus, the results obtained with two
different nuclear proteins (Gal4-DBD and EGFPnuc) have demonstrated
that RFP harbors a functional NES in its coiled-coil region. In mouse,
RFP homodimerization through the coiled-coil region was reported to be
important for RFP localization (18). Human RFP can dimerize in a
similar way through its coiled-coil
region.2 Because the NES is
in the coiled-coil region of RFP, we investigated whether point
mutations in the NES affect the homodimerization using a yeast
two-hybrid system. The results showed that wild-type RFP was able to
interact with RFPmut, indicating that the point mutations in the NES
did not destroy the overall structure of the coiled-coil
domain.2
The NES Function of RFP Is Masked in HepG2 Cells--
In contrast
to NIH3T3 cells, RFP is localized predominantly in the nucleus in HepG2
cells. To address whether the NES of RFP is functional in HepG2 cells,
the Gal4-DBD-RFP fusion proteins were also expressed in HepG2 cells,
and their localizations were analyzed as in NIH3T3 cells (Fig.
5A). The coiled-coil region of
RFP was able to relocate the Gal4-DBD protein to the cytoplasm, whereas
mutations in the NES reestablished the nuclear localization of the
Gal4-DBD fusion protein, indicating that the NES of RFP is also
functional in HepG2 cells. In contrast, however, the fusion protein
containing full-length RFP was still localized in the nucleus, and this
was unaffected by point mutations in the putative NES
(Gal4-DBD-RFPmut). These results indicate that the activity of NES in
full-length RFP is masked by its interaction with other domain(s) in
the RFP protein or with other protein(s).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 5.
Function of the RFP NES in HepG2 cells.
Panel A, effect of RFP on the localization of Gal4-DBD in
HepG2 cells. Gal4-DBD-RFP fusion proteins described in the legend of
Fig. 4A were expressed in HepG2 cells, and their
localizations were analyzed with anti-Gal4-DBD antibody as described in
Fig. 4A. Panel B, effect of RFP on the
localization of a nuclear form of GFP in HepG2 cells. RFP proteins
fused to nuclear GFP (Fig. 4B) were expressed in HepG2
cells, and their localizations were analyzed as described in Fig.
4B.
|
|
In addition to using Gal4-DBD fusion proteins, RFP fused to the nuclear
form of GFP (EGFPnuc) was also expressed in HepG2 cells (Fig.
5B). Similar to the results obtained with the Gal4-DBD fusion proteins, full-length RFP failed to relocalize EGFPnuc to the
cytoplasm of HepG2 cells. The full-length RFP fusion protein was found
in fine dot-like structures in the nucleus, whereas NES mutations led
to localization of the fusion protein to defined nuclear dots
resembling those of PML. Fusion of EGFPnuc with the RFP mutant lacking
the coiled-coil region did not affect nuclear localization of the RFP.
These results indicate that the activity of NES in full-length RFP is
masked by its interaction with other domain(s) in the RFP protein or
with other protein(s).
NLS in the C-terminal Portion of RFP--
Because RFP protein is
localized to the nucleus under certain conditions, RFP protein should
also contain an NLS. Therefore, we sought to locate the NLS within RFP.
First of all, we determined if a previously described putative NLS
(amino acids 156-162) in the N-terminal half of the coiled-coil region
of RFP (18) had functional activity (Fig.
6A). We constructed a vector
expressing GFP fused to a 527-amino acid region from the
Escherichia coli lacZ gene product, whose large size
precluded its passive diffusion into the nucleus. A fusion protein
consisting of GFP-LacZ linked to the N-terminal part of coiled-coil
region of RFP (RFP132-169) was not localized predominantly to the
nucleus of HepG2 cells. These results indicated that this putative NLS
was not active on its own, but other portion(s) or additional
portion(s) were required for a functional NLS. To identify the NLS in
RFP, we examined the localization of various GFP-RFP fusion proteins in HepG2 cells (Fig. 6B). The GFP fusion protein containing the
full-length RFP was localized predominantly in the nucleus of HepG2
cells, indicating that the NES activity of RFP is masked in HepG2 cells and that the NLS of RFP predominantly determines its cellular localization. Deletion of either the Ring finger or the entire RBCC
domain, which comprises the RING finger, B box, and coiled-coil region,
had no effect on the nuclear localization of GFP-RFP. Furthermore, the
GFP fusion containing the RBCC domain of RFP was localized
predominantly to the cytoplasm. These results suggested that the NLS
was located in the C-terminal portion of RFP. However, no region in the
C-terminal portion of RFP displays significant homology with the
consensus NLS sequence. Therefore, we were unable to narrow the region
of RFP containing the NLS.

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 6.
Analysis of NLS in the RFP protein.
Panel A, a putative NLS-like sequence in the RFP coiled-coil
region does not act as an NLS. The control GFP-LacZ fusion protein and
the GFP-LacZ fusion protein carrying the N-terminal portion of the
coiled-coil region of RFP were expressed in HepG2 cells, and their
localizations were analyzed as described in Fig. 1B.
Panel B, localization of an NLS in the C-terminal half of
RFP. A series of GFP fusion proteins carrying various portions of RFP
was expressed in HepG2 cells and visualized as described in Fig.
1B.
|
|
Regulation of RFP Localization by PKC Signaling--
The NES of
RFP is active in NIH3T3 cells but masked in HepG2 cells. This raises
the possibility that some specific signals or factors may regulate the
NES activity of RFP. We therefore investigated signals that could
induce changes in the localization of RFP in NIH3T3 and HepG2 cells.
Among the various activators and inhibitors of the different signaling
pathways tested, the PKC activator TPA showed the greatest effect (data
not shown). Therefore, the effect of PKC-mediated signaling on RFP
localization was studied further. Treatment of HepG2 cells with TPA for
1 h induced cytoplasmic localization of RFP in about 55% of cells (Fig. 7A). In these cells,
almost complete relocalization of RFP to the cytoplasm was observed,
and RFP appeared in dot-like structures similar to those found in
NIH3T3 cells. The change in the cellular localization of RFP was only
transient because HepG2 cells treated with TPA for 24 h showed
nearly exclusive nuclear staining for RFP. To determine whether
TPA-induced nuclear export of RFP is dependent on the NES in the
coiled-coil domain, HepG2 cells expressing FLAG-tagged RFP were treated
for 1 h with TPA plus LMB. Addition of LMB significantly blocked
the release of RFP from the nucleus in HepG2 cells (Fig.
7A). Furthermore, in contrast to wild-type RFP, RFPmut
harboring a mutated NES was unable to respond to TPA treatment (Fig.
7A). These results indicate that the NES is required for the
TPA-induced relocalization of RFP from the nucleus to the cytoplasm in
HepG2 cells.

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 7.
Effect of PKC signaling on RFP
localization. Panel A, stimulation of nuclear export of
RFP by TPA. FLAG-tagged wild-type or mutated RFP was expressed in HepG2
cells. 1 or 2 days after transfection, cells were treated with 100 ng/ml TPA for 1 h or 24 h or with 100 ng/ml TPA plus 2 ng/ml
LMB for 1 h. RFP localization was determined with an anti-FLAG
antibody as described in Fig. 1B. Two types of staining
pattern, which showed the predominantly nuclear or cytoplasmic RFP,
were observed, and the cells showing uniform distribution both in
nucleus and cytoplasm were not detected. Approximately 50-150 cells
were examined, and the percentages of cells with cytoplasmic RFP are
expressed in a bar graph on the right.
Panel B, stimulation of nuclear export of RFP by PKC . The
expression vector for FLAG-tagged RFP was transfected into HepG2 cells
together with vectors expressing wild-type or activated forms of PKC
or a control vector. RFP and PKC localizations were examined with an
anti-FLAG antibody and a PKC -specific antibody, respectively, as
described in Fig. 1B. The numbers of cells with cytoplasmic
RFP were counted, and the results of each experiment are shown in a
bar graph on the right.
|
|
PKC comprises a growing gene family with up to 12 distinct members. To
identify the PKC isoform regulating RFP shuttling, RFP was coexpressed
in HepG2 cells together with different PKC isoforms (PKC , PKC ,
and PKC ) and RFP localization examined (Fig. 7B).
Wild-type PKC had only a minor effect on RFP localization, whereas a
constitutively active form of PKC induced the release of RFP from
the nucleus in about 21% of cells with both proteins being localized
to the cytoplasm. Cotransfection with either control plasmid or
expression vectors for other PKC isoforms had no effect on the nuclear
localization of RFP (data not shown).
PKC-mediated nuclear export of RFP was studied further in NIH3T3 and
HepG2 cells using different PKC inhibitors. The TPA-induced nuclear
export of RFP in HepG2 cells was blocked efficiently by the PKC
inhibitors H7 and staurosporine (Fig.
8A). Treatment of NIH3T3 cells
with the same inhibitors for 24 h also blocked the nuclear export
of RFP and induced nuclear accumulation of RFP, as observed with LMB,
without affecting the viability of the cells (Fig. 8B).
These results further support our findings that the nuclear export of
RFP is positively regulated by PKC activation.

View larger version (31K):
[in this window]
[in a new window]
|
Fig. 8.
Effect of PKC inhibitors on RFP
localization. Panel A, inhibition of TPA-induced
nuclear export of RFP by PKC inhibitors in HepG2 cells. HepG2 cells
were transfected with the FLAG-tagged RFP expression vector and treated
for 1 h with 50 ng/ml TPA or 50 ng/ml TPA plus 200 µM H7 or 20 nM staurosporine.
Immunohistochemistry was performed with an anti-FLAG antibody as
described in Fig. 1B, and the percentages of cells with
cytoplasmic RFP are shown in the bar graph on the
right. Panel B, inhibition of the nuclear export
of RFP by PKC inhibitors in NIH3T3 cells. NIH3T3 cells expressing
FLAG-tagged RFP were treated similarly with 100 µM H7 or
10 nM staurosporine, and the results are indicated as
described above.
|
|
Because RFP showed distinct localizations in NIH3T3 and HepG2 cells, we
looked for differences in PKC protein levels and activities between
these cell lines (Fig. 9A).
Western blot analysis of whole cell extracts from NIH3T3 and HepG2
cells using anti-PKC and anti-phosphorylated PKC showed similar
amounts of PKC and phosphorylated PKC in both cell lines. Similar
values were also found for total PKC activity in both cell lines,
indicating that the differential pattern of RFP localization was not
caused by differences in the amounts or activities of PKC. Because
PKC has been found in the nucleus of activated NIH3T3 and vascular
smooth muscle cells (48-50), the possibility of direct phosphorylation
of RFP by PKC was investigated by mutating five putative PKC
phosphorylation sites in RFP, identified in a PhosphoBase data base
search (51). Neither single mutations (positions T83A, S192A, S290A,
T295A, or T453A) nor mutations at all five putative PKC phosphorylation
sites together affected RFP localization in NIH3T3 or HepG2 cells, or
the TPA-induced nuclear release of RFP in HepG2 cells.2

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 9.
Effect of various signaling pathways on RFP
localization. Panel A, PKC levels in NIH3T3 and HepG2
cells. In the left image, whole cell extracts were prepared
from NIH3T3 and HepG2 cells, and 50 µg of total protein from each
extract was analyzed by Western blot with anti-PKC and
anti-phosphorylated PKC -specific antibodies. In the right
image, PKC activity in NIH3T3 and HepG2 cells was measured, and
the average results of three experiments are indicated by a bar
graph. Panel B, effect of various signaling pathways on
the subcellular localization of RFP. The FLAG-tagged RFP expression
vector was cotransfected with the Ha-ras or JNK1 expression
vector or control vectors (pcEXV-1 and pSR 0). Immunohistochemistry
was performed with an anti-FLAG antibody as described in Fig.
1B, and the percentages of cells with cytoplasmic RFP are
shown in the bar graph on the right.
|
|
The similar level of PKC activity in NIH3T3 and HepG2 cells suggested
that additional signaling pathways might be also involved in the
control of RFP localization. Therefore, the effects of activated Ras
and JNK1 on the localization of RFP in HepG2 cells were analyzed
further (Fig. 9B). When the activated form of
Ha-ras or HA-tagged JNK1 was coexpressed together with
FLAG-tagged RFP, a partial release of RFP from the nucleus was
observed. Nuclear localization of JNK1 was observed in about a quarter
of the transfected HepG2 cells, and cytoplasmic localization of RFP was
only observed in cells with nuclear JNK1 (Fig. 9B). In
addition, sorbitol treatment of transfected HepG2 cells increased the
number of cells with nuclear JNK1 and cytoplasmic RFP.2
These results suggest that JNK1-mediated phosphorylation events in the
nucleus result in the nuclear export of RFP. Thus, additional signaling
pathways including ras and JNK1 may be involved in the PKC-mediated nuclear export of RFP. Between NIH3T3 and HepG2 cells, the
amount or activity of some factors, which act as the transducer of
these signaling pathways, may be different.
 |
DISCUSSION |
For the control of cell growth and differentiation, sophisticated
regulatory mechanisms are necessary for specific and selective responses to various signals. Cells use several distinct mechanisms for
signal transduction, including those that alter the cellular localization of individual regulatory factors. Here we studied the
cellular localization of RFP in NIH3T3 and HepG2 cells and the
regulation of this process in response to external signals. Our study
demonstrates that the coiled-coil domain of RFP containing the
leucine-rich NES controls shuttling of RFP between the nucleus and the
cytoplasm. The NES was functionally active as RFP containing a mutation
in the putative NES accumulated in the nucleus of NIH3T3 cells and the
CRM1-specific inhibitor LMB blocked nuclear export of RFP (Fig. 3).
This mutated RFP was still able to homodimerize through its coiled-coil
region,2 indicating that the point mutations did not affect
the overall structure of the coiled-coil domain but specifically
affected the function of the NES. In addition, Gal4-DBD and a nuclear
form of GFP (EGFPnuc) were localized to the cytoplasm of NIH3T3 cells when fused to the NES domain of RFP (Fig. 4).
The distinct localization of RFP in NIH3T3 and HepG2 cells argues for
tight regulation of the activity of the NES, resulting in only limited
exchange between nuclear and cytoplasmic RFP. This regulation might
depend on masking of the NES by conformational changes induced by
post-translational modification. In most cases, nuclear transport and
export are regulated by phosphorylation, as shown for the yeast
transcription factor Pho4 (52, 53) and the mammalian factor NF-AT (24).
Regulatory domains can also be masked by their binding to other
inhibitory factors, as shown for NF- B (54) and I B (25, 26), or
regulated by homodimerization, which controls the shuttling of
mitogen-activated protein kinase (55, 56). As in the case of
mitogen-activated protein kinase, RFP dimerizes through its coiled-coil
region with potentially important consequences for RFP localization
(18). However, it is unlikely that dimerization masks the NES, because
mutations in the NES did not affect RFP homodimerization.2
Another possibility to explain the distinct localization of RFP in
NIH3T3 and HepG2 cells is their different diffusion limit. Protein
import and export are regulated by a complex machinery, which includes
soluble components and nuclear pores (for review, see Ref. 31).
Nuclear pores are gated channels composed of at least 50 proteins, many
of which have not been characterized. Particles of <9 nm in
diameter or globular proteins of less than 50-69 kDa can enter the
nucleus by diffusion, whereas larger objects should be actively
transported. However, the size limitation for diffusion varies
depending on the cell types. Therefore, we cannot completely exclude
the possibility that the distinct localization of RFP in NIH3T3 and
HepG2 cells partly depends on their different diffusion limit.
RFP localization to the cytoplasm of NIH3T3 cells as well as to the
nucleus of HepG2 cells is largely dependent on the integrity of the
coiled-coil region. The coiled-coil domain is especially required for
the dot-like structures in the cytoplasm of NIH3T3 cells, which
resemble those of the endoplasmic reticulum. However, the mechanism
responsible for the generation of the dot-like structures is unknown
because no targeting sequence for the endoplasmic reticulum or the
Golgi apparatus was found in RFP. However, it is of interest to note
within this context that the RFP-binding protein Int-6, although
localized predominantly to the nucleus (57), was also characterized as
a subunit of the translation initiation factor eIF3 (58). Binding of
RFP to other proteins, such as Int-6, through the coiled-coil region or
the whole RBCC domain might be responsible for the generation or
stability of the dot-like structures. A similar dot-like localization
in the cytoplasm was also observed for the oncogenic RFP-RET fusion
protein, suggesting a role for the RBCC motif in the relocalization of
the RET kinase. It is likely that the oncogenic potential of the
RFP-RET oncogene depends on the localization mediated by the RBCC motif
because RET-RFP proteins with point mutations in the RBCC motif have no transforming activity (14).
Integration of RFP into PML nuclear bodies by direct binding to PML
(21) and Int-6 (22) has been described. Although only a small portion
of RFP was found in the nuclear bodies of HepG2 cells, nuclear
accumulation of RFP, which was induced, for instance, by mutating the
NES, increased the number of cells with RFP localized to dot-like
structures within the nucleus. This observation indicates the
possibility that RFP associates with PML nuclear bodies. Deletion of
the entire coiled-coil region led to almost uniform distribution of the
GFP-RFP fusion protein in HepG2 cells, indicating that the coiled-coil
region is required for RFP association with PML nuclear bodies. Because
an RFP mutant that cannot bind to PML was reported to be nuclear in
HeLa cells (21), the RFP interaction with PML may be not required for
nuclear localization of RFP.
The effects of various signal transduction pathways on RFP localization
were analyzed. These studies revealed an important role for PKC in the
control of RFP shuttling, which is reminiscent of
PKC-dependent regulation of nuclear localization of
diacylglycerol kinase (59). PKC activation by TPA induced fast
nuclear export of RFP in HepG2 cells, which was dependent on a
functional NES (Fig. 7). Experiments with various PKC isoforms in
transfected HepG2 cells identified PKC as a possible mediator of RFP
shuttling. However, overexpression of a constitutively active form of
PKC had only a limited effect on shuttling, probably reflecting the high endogenous PKC levels of HepG2 cells (60). The PKC inhibitors H7 and staurosporine blocked nuclear export of RFP in NIH3T3 cells (Fig. 8), suggesting that PKC signaling can control RFP localization in
cell lines other than HepG2. We found no evidence for direct PKC
regulation of the differential localization of RFP in NIH3T3 and HepG2
cells because both cell lines had comparable PKC levels and activities
(Fig. 9). Although PKC was reported to be present in the nucleus of
stimulated cells (48-50), we found no evidence for the direct
phosphorylation of RFP by PKC. Although PKC does not phosphorylate RFP
directly, it may still be an important regulator for RFP function. In
this context it is interesting to note that changes in the levels of
different PKC isoforms, including PKC , correlate with high RFP
levels during spermatogenesis (61, 62), suggesting that RFP may have a
function in testis.
In addition to PKC, we also observed that nuclear export of RFP in
HepG2 cells was enhanced by coexpression of activated ras or
JNK1 (Fig. 9). Signaling pathways involving PKC, ras, and
JNK interact with each other. For instance, an activated
c-Ha-ras oncogene induces an increased expression of PKC
(63), and PKC is involved in the activation of JNK (64). Although
further analysis will be required to identify the mechanisms through
which PKC signaling positively regulates the nuclear export of RFP, our
present results indicate that localization of RFP is regulated by
complex processes in a cell type-specific manner.
 |
ACKNOWLEDGEMENTS |
We are grateful to M. Takahashi for the human
RFP cDNA, M. Noda for the Ha-ras expression vector, M. Karin for the JNK1 expression vector, M. Yoshida for LMB, and P. Chambon for expression vectors.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Laboratory of
Molecular Genetics, RIKEN Tsukuba Institute, 3-1-1 Koyadai, Tsukuba, Ibaraki 305-0074, Japan. Tel.: 81-298-36-9031; Fax:
81-298-36-9030; E-mail: sishii@rtc.riken.go.jp.
Published, JBC Papers in Press, October 8, 2001, DOI 10.1074/jbc.M108077200
2
M. Harbers and S. Ishii, unpublished results.
 |
ABBREVIATIONS |
The abbreviations used are:
RBCC, RING-B
box-coiled-coil;
EGFP, enhanced green fluorescent protein;
PML, promyelocytic leukemia protein;
RFP, Ret finger protein;
NES, nuclear export signal;
NLS, nuclear localization sequence;
PKC, protein
kinase C;
TPA, 12-O-tetradecanoylphorbol-13-acetate;
LMB, leptomycin B;
GFP, green fluorescent protein;
JNK, Jun N-terminal
protein kinase;
DBD, DNA binding domain.
 |
REFERENCES |
| 1.
|
Douarin, B. L.,
Nielsen, A. L.,
Garnier, J.-M.,
Ichinose, H.,
Jeanmougin, F.,
Losson, R.,
and Chambon, P.
(1996)
EMBO J.
15,
6701-6715[Medline]
[Order article via Infotrieve]
|
| 2.
|
Saurin, A. J.,
Borden, K. L. B.,
Boddy, M. N.,
and Freemont, P. S.
(1996)
Trends Biol. Sci.
21,
208-453
|
| 3.
|
Borden, K. L. B.,
and Freemont, P. S.
(1996)
Curr. Opin. Struct. Biol.
6,
395-401[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Borden, K. L. B.
(1998)
Biochem. Cell Biol.
76,
351-358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Lupas, A.
(1996)
Trends Biochem. Sci.
21,
375-382[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Kakizuka, A.,
Miller, W. H., Jr.,
Umesono, K.,
Warrell, R. P., Jr.,
Frankel, S. R.,
Murty, V. V.,
Dmitrovsky, E.,
and Evans, R. M.
(1991)
Cell
66,
663-674[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Thé, H. d.,
Lavau, C.,
Marchio, A.,
Chomienne, C.,
Degos, L.,
and Dejean, A.
(1991)
Cell
66,
675-684[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Stunnenberg, H. G.,
Garcia-Jimenez, C.,
and Betz, J. L.
(1998)
Biochim. Biophys. Acta
1423,
F15-F33
|
| 9.
|
Melnick, A.,
and Light, J. D.
(1999)
Blood
93,
3167-3215[Free Full Text]
|
| 10.
|
Douarin, B. L.,
Zechel, C.,
Garnier, J. M.,
Lutz, Y.,
Tora, L.,
Pierrat, B.,
Heery, D.,
Gronemeyer, H.,
Chambon, P.,
and Losson, R.
(1995)
EMBO J.
14,
2020-2033[Medline]
[Order article via Infotrieve]
|
| 11.
|
Weering, D. H. J. v.,
and Bos, J. L.
(1998)
Rec. Results Cancer Res.
154,
271-281[Medline]
[Order article via Infotrieve]
|
| 12.
|
Takahashi, M.,
Ritz, J.,
and Cooper, G. M.
(1985)
Cell
42,
581-588[CrossRef][Medline]
[Order article via Infotrieve]
|
| 13.
|
Takahashi, M.,
and Cooper, G. M.
(1987)
Mol. Cell. Biol.
7,
1378-1385[Abstract/Free Full Text]
|
| 14.
|
Hasegawa, N.,
Iwashita, T.,
Asai, N.,
Murakami, H.,
Iwata, Y.,
Isomura, T.,
Goto, H.,
Hayakawa, T.,
and Takahashi, M.
(1996)
Biochem. Biophys. Res. Commun.
225,
627-631[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Zhong, S.,
Delva, L.,
Rachez, C.,
Cenciarelli, C.,
Gandini, D.,
Zhang, H.,
Kalantry, S.,
Freedman, L. P.,
and Pandolfi, P. P.
(1999)
Nat. Genet.
23,
287-295[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Cao, T.,
Shannon, M.,
Handel, M. A.,
and Etkin, L. E.
(1996)
Dev. Genet.
19,
309-320[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Tezel, G.,
Nagasaka, T.,
Iwahashi, N.,
Asai, N.,
Iwashita, T.,
Sakata, K.,
and Takahashi, M.
(1999)
Pathol. Int.
49,
881-886[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Cao, T.,
Borden, K. L. B.,
Freemont, P. S.,
and Etkin, L. D.
(1997)
J. Cell Sci.
110,
1563-1571[Abstract]
|
| 19.
|
Isomura, T.,
Tamiya-Koizumi, K.,
Suzuki, M.,
Yoshida, S.,
Taniguchi, M.,
Matsuyama, M.,
Ishigaki, T.,
Sakuma, S.,
and Takahashi, M.
(1992)
Nucleic Acids Res.
20,
5305-5310[Abstract/Free Full Text]
|
| 20.
|
Dyck, J. A.,
Maul, G. G.,
Miller, W. H., Jr.,
Chen, J. D.,
Kakizuka, A.,
and Evans, R. M.
(1994)
Cell
76,
333-343[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Cao, T.,
Duprez, E.,
Borden, K. L. B.,
Freemont, P. S.,
and Etkin, L. D.
(1998)
J. Cell Sci.
111,
1319-1329[Abstract]
|
| 22.
|
Morris-Desbois, C.,
Bochard, V.,
Reynaud, C.,
and Jalinot, P.
(1999)
J. Cell Sci.
112,
3331-3342[Abstract]
|
| 23.
|
Shimono, Y.,
Murakami, H.,
Hasegawa, Y.,
and Takahashi, M.
(2000)
J. Biol. Chem.
275,
39411-39419[Abstract/Free Full Text]
|
| 24.
|
Crabtree, G. R.
(1999)
Cell
96,
611-614[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Rodriguez, M. S.,
Thompson, J.,
Hay, R. T.,
and Dargemont, C.
(1999)
J. Biol. Chem.
274,
9108-9115[Abstract/Free Full Text]
|
| 26.
|
Johnson, C.,
Antwerp, D. V.,
and Hope, T. J.
(1999)
EMBO J.
18,
6682-6693[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Jans, D. A.,
Xiao, C.-Y.,
and Lam, M. H. C.
(2000)
BioEssays
22,
532-544[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Görlich, D.
(1997)
Curr. Opin. Cell Biol.
9,
412-419[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Adam, S. A.
(1999)
Curr. Opin. Cell Biol.
11,
402-406[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Turpin, P.,
Ossareh-Nazari, B.,
and Dargemont, C.
(1999)
FEBS Lett.
452,
82-86[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Nakielny, S.,
and Dreyfuss, G.
(1999)
Cell
99,
677-690[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Fukuda, M.,
Asano, S.,
Nakamura, T.,
Adachi, M.,
Yoshida, M.,
Yanagida, M.,
and Nishida, E.
(1997)
Nature
390,
308-311[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Fornerod, M.,
Ohno, M.,
Yoshida, M.,
and Mattaj, I. W.
(1997)
Cell
90,
1051-1060[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Ossareh-Nazari, B.,
Bachelerie, F.,
and Dargemont, C.
(1997)
Science
278,
141-144[Abstract/Free Full Text]
|
| 35.
|
Tora, L.,
White, J.,
Brou, C.,
Tasset, D.,
Webster, N.,
Scheer, E.,
and Chambon, P.
(1989)
Cell
59,
477-487[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Ueda, Y.,
Hirai, S.,
Osada, S.,
Suzuki, A.,
Mizuno, K.,
and Ohno, S.
(1996)
J. Biol. Chem.
271,
23512-23519[Abstract/Free Full Text]
|
| 37.
|
Khan, M. M.,
Nomura, T.,
Kim, H.,
Kaul, S. C.,
Wadhwa, R.,
Shinagawa, T.,
Ichikawa-Iwata, E.,
Zhong, S.,
Pandolfi, P. P.,
and Ishii, S.
(2001)
Mol. Cell
7,
1233-1243[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Vojtek, A. B.,
Hollenberg, S. M.,
and Cooper, J. A.
(1993)
Cell
74,
205-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 39.
|
Douarin, B. L.,
Pierrat, B.,
Baur, E. v.,
Chambon, P.,
and Losson, R.
(1995)
Nucleic Acids Res.
23,
876-878[Free Full Text]
|
| 40.
|
Seipel, K.,
Georgiev, O.,
and Schaffner, W.
(1992)
EMBO J.
11,
4961-4968[Medline]
[Order article via Infotrieve]
|
| 41.
|
Fischer, U.,
Huber, J.,
Boelens, W. C.,
Mattji, I. W.,
and Lührmann, R.
(1995)
Cell
82,
475-483[CrossRef][Medline]
[Order article via Infotrieve]
|
| 42.
|
Wen, W.,
Meinkoth, J. L.,
Tsien, R. Y.,
and Taylor, S. S.
(1995)
Cell
82,
463-473[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
van Hengel, J.,
Vanhoenacker, P.,
States, K.,
and van Roy, F.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
7980-7985[Abstract/Free Full Text]
|
| 44.
|
Toyoshima, F.,
Moriguchi, T.,
Wada, A.,
Fukuda, M.,
and Nishida, E.
(1998)
EMBO J.
17,
2728-2735[CrossRef][Medline]
[Order article via Infotrieve]
|
| 45.
|
Engel, K.,
Kotlyarov, A.,
and Gaestel, M.
(1998)
EMBO J.
17,
3363-3371[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Wolf, B.,
Sanglier, J. J.,
and Wang, Y.
(1997)
Chem. Biol.
4,
139-147[CrossRef][Medline]
[Order article via Infotrieve]
|
| 47.
|
Hoshino, H.,
Kobayashi, A.,
Yoshida, M.,
Kudo, N.,
Oyake, T.,
Motohashi, H.,
Hayashi, N.,
Yamamoto, M.,
and Igarashi, K.
(2000)
J. Biol. Chem.
275,
15370-15376[Abstract/Free Full Text]
|
| 48.
|
Haller, H.,
Quass, P.,
Lindschau, C.,
Luft, F. C.,
and Distler, A.
(1994)
Hypertension
23,
848-852[Abstract/Free Full Text]
|
| 49.
|
Schmalz, D.,
Hucho, F.,
and Buchner, K.
(1998)
J. Cell Sci.
111,
1823-1830[Abstract]
|
| 50.
|
Buchner, K.
(1995)
Eur. J. Biochem.
228,
211-221[Medline]
[Order article via Infotrieve]
|
| 51.
|
Kreegipuu, A.,
Blom, N.,
Brunak, S.,
and Järv, J.
(1998)
FEBS Lett.
430,
45-50[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Kaffman, A.,
Rank, N. M.,
and O'Shea, E. K.
(1998)
Genes Dev.
12,
2673-2683[Abstract/Free Full Text]
|
| 53.
|
Kaffman, A.,
Rank, N. M.,
O'Neill, E. M.,
Huang, L. S.,
and O'Shea, E. K.
(1998)
Nature
396,
482-486[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Harhaj, E. W.,
and Sun, S.-C.
(1999)
Mol. Cell. Biol.
19,
7088-7095[Abstract/Free Full Text]
|
| 55.
|
Adachi, M.,
Fukuda, M.,
and Nishida, E.
(1999)
EMBO J.
18,
5347-5358[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Cobb, M. H.,
and Goldsmith, E. J.
(2000)
Trends Biochem. Sci.
25,
7-9[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Desbois, C.,
Rousset, R.,
Bantignies, F.,
and Jalinot, P.
(1996)
Science
273,
951-953[Abstract]
|
| 58.
|
Asano, K.,
Merrick, W. C.,
and Hershey, J. W.
(1997)
J. Biol. Chem.
272,
23477-23480[Abstract/Free Full Text]
|
| 59.
|
Topham, M. K.,
Bunting, M.,
Zimmerman, G. A.,
McIntyre, T. M.,
Blackshear, P. J.,
and Prescott, S. M.
(1998)
Nature
394,
697-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 60.
|
Fandrey, J.,
Huwiler, A.,
Frede, S.,
Pfeilschifter, J.,
and Jelkmann, W.
(1994)
Eur. J. Biochem.
226,
335-340[Medline]
[Order article via Infotrieve]
|
| 61.
|
Zini, N.,
Matteucci, A.,
Sabatelli, P.,
Valmori, A.,
Caramelli, E.,
and Maraldi, N. M.
(1997)
Eur. J. Cell Biol.
72,
142-150[Medline]
[Order article via Infotrieve]
|
| 62.
|
Takahashi, M.,
Inaguma, Y.,
Hiai, H.,
and Hirose, F.
(1988)
Mol. Cell. Biol.
8,
1853-1856[Abstract/Free Full Text]
|
| 63.
|
Borner, C.,
Guadagno, S. N.,
Hsiao, W. W.,
Fabbro, D.,
Barr, M.,
and Weinstein, I. B.
(1992)
J. Biol. Chem.
267,
12900-12910[Abstract/Free Full Text]
|
| 64.
|
Nagao, M.,
Yamauchi, J.,
Kaziro, Y.,
and Itoh, H.
(1998)
J. Biol. Chem.
273,
22892-22898[Abstract/Free Full Text]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. A. Matheny and M. A. White
Signaling Threshold Regulation by the Ras Effector IMP
J. Biol. Chem.,
April 24, 2009;
284(17):
11007 - 11011.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sun, V. Montana, K. Chellappa, Y. Brelivet, D. Moras, Y. Maeda, V. Parpura, B. M. Paschal, and F. M. Sladek
Phosphorylation of a Conserved Serine in the Deoxyribonucleic Acid Binding Domain of Nuclear Receptors Alters Intracellular Localization
Mol. Endocrinol.,
June 1, 2007;
21(6):
1297 - 1311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Zha, K.-J. Han, L.-G. Xu, W. He, Q. Zhou, D. Chen, Z. Zhai, and H.-B. Shu
The Ret Finger Protein Inhibits Signaling Mediated by the Noncanonical and Canonical I{kappa}B Kinase Family Members
J. Immunol.,
January 15, 2006;
176(2):
1072 - 1080.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. DeLong, G. M. C. Bonamy, E. N. Fink, and L. A. Allison
Nuclear Export of the Oncoprotein v-ErbA Is Mediated by Acquisition of a Viral Nuclear Export Sequence
J. Biol. Chem.,
April 9, 2004;
279(15):
15356 - 15367.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Le Gallic, L. Virgilio, P. Cohen, B. Biteau, and G. Mavrothalassitis
ERF Nuclear Shuttling, a Continuous Monitor of Erk Activity That Links It to Cell Cycle Progression
Mol. Cell. Biol.,
February 1, 2004;
24(3):
1206 - 1218.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Ito, C. Jiang, K. Krumm, X. Zhang, J. Pecha, J. Zhao, Y. Guo, R. G. Roeder, and H. Xiao
TIP30 Deficiency Increases Susceptibility to Tumorigenesis
Cancer Res.,
December 15, 2003;
63(24):
8763 - 8767.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|